4333results about "Embryonic cells" patented technology

A method for automated, artificial-intelligence-based COC retrieval includes using an artificial intelligence / machine learning system (AI / ML system) to optically scan a follicular fluid sample to produce an image object using an imaging system that includes a microscopy system, a camera system, and a lighting system. The method includes comparing the image object to a predetermined threshold using an AI / ML system, wherein the predetermined threshold is at least in part an optical pattern with a probability of corresponding to a cumulus-oocyte-complex (COC). The method includes identifying a COC within the follicular fluid sample based at least in part on the image object satisfying the predetermined threshold. The method includes determining a COC location within the follicular fluid sample based at least in part on identifying a region of the image object corresponding to an optical pattern within the image object that satisfies the predetermined threshold.

The invention belongs to the technical field of molecular biology and genetics, and particularly relates to a method for editing cattle genes based on Pro-iCHI. The invention provides a method for editing cattle genes based on Pro-iCHI, which comprises the following steps: transiently expressing protamine in cattle AG-haESCs after gene editing, and injecting into mature oocytes to obtain reconstructed embryos. The protamine can remove abnormal DNA methylation generated by an oocyte cytoplasm injection haploid stem cell technology, cell nucleuses are compressed into a sperm-like structure, the obtained bovine Pro-iCHI embryo can smoothly develop into a blastocyst, and the ratio of the blastocyst to the blastocyst obtained by in-vitro fertilization is equivalent. Moreover, the protamine coding gene is inserted into the saccharomyces cerevisiae protein expression vector and then is subjected to transient expression, so that the protamine coding gene cannot be integrated into a genome to cause insertion of an exogenous gene while abnormal DNA methylation is erased.

The present disclosure provides methods of differentiating pluripotent stem cells, including induced pluripotent stem cells, into lineage-specific floor plate midbrain progenitor cells, determined dopaminergic neuronal progenitor cells, committed dopaminergic neuronal progenitor cells and / or dopaminergic neuronal cells. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease, and articles of manufacture and kits for use thereof.

The invention relates to compositions (e.g., pharmaceutical compositions), uses, methods, non-therapeutic and therapeutic methods related to senolytic agents encapsulated or comprised in Muse cell derived extracellular vesicles (e.g. exosomes). Such compositions and methods are useful for specifically killing senescent cells and reverting any symptoms, disorders or diseases associated with senescence.

The invention relates to a heart organoid and an in-vitro preparation method thereof, and belongs to the technical field of stem cells. The invention provides a heart organoid. The heart organoid is obtained by induced culture of an adherent pluripotent stem cell mass; the adherent pluripotent stem cell mass is obtained by adherent culture of a suspended pluripotent stem cell mass; the suspension pluripotent stem cell mass is obtained by suspension culture of pluripotent stem cells. According to the in-vitro preparation process of the heart organoid, after pluripotent stem cells form balls, the pluripotent stem cell balls are subjected to staged induced differentiation under adherent culture, so that cell subtypes such as epicardial cells and the like can be generated without additional addition or additional stimulation of signal channels, and the heart organoid is more homogeneous. The self-occurring multi-lineage coexisting heart organoid can better simulate biological events derived from multiple cell types and multiple cell subtypes in the early development process of an embryonic heart, and has great application prospects in exploration of pathogenic factors and potential treatment targets of congenital heart diseases.

The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1 and application thereof, and relates to the technical field of biology. The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1. The nucleotide sequence of the enhancer RNA molecule MZGAe1 is as shown in SEQ ID NO: 1; meanwhile, the invention further provides a specific sgRNA sequence for activating the molecule in a targeted manner and a recombinant vector of the specific sgRNA sequence. Expression of endogenous MZGAe1 of cells is specifically activated by adopting a CRISPR activation technology, and conversion of mouse embryonic stem cells to bicellular-like cells can be efficiently promoted. By providing a brand-new endogenous targeted MZGAe1 accurate activation tool, the efficient transformation of wild mouse embryonic stem cells to bicellular cells can be realized only under the condition of endogenous activation of single enhancer RNA molecule MZGAe1, the proportion is at least increased by 5%, the expression of a totipotent marker gene ZSCAN4 is activated, and the expression of the totipotent marker gene ZSCAN4 is promoted. And an efficient and specific brand-new research tool and scheme are provided for researching zygote genome activation, embryonic development early events and cell reprogramming.

The invention discloses a pig chimeric embryo culture medium and application thereof in effectively improving the in-vitro chimeric ability of pig embryonic stem cells, and belongs to the technical field of bioengineering. According to the pig chimeric embryo culture medium disclosed by the invention, a neutral culture environment for promoting synchronous development of stem cells and embryos is created by accurately regulating and controlling growth factors, nutrient substances and other key components in the culture medium. On the basis, overexpression of anti-apoptosis factors, optimization of microinjection conditions and adoption of a laser-assisted incubation means are combined, so that the chimeric efficiency is further improved, integration of the stem cells and embryos is effectively supported, the chimeric efficiency is improved, and a reliable in-vitro tool is provided for evaluating the chimeric ability and pluripotency of the pig stem cells.

The invention provides human placenta-derived vasogenic stem cells (hPASCs) and application thereof. The human placenta-derived angiogenic stem cells (hPASCs) disclosed by the invention are preserved in China Center for Type Culture Collection, Wuhan University, Wuhan, China; the preservation date is April 2, 2025; the preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: The hPASCs disclosed by the invention contain angiogenic cell subgroups, have stem cell stemness, have an angiogenesis effect in vivo and in vitro, and can be used for treatment of diseases such as cardiovascular diseases and vascularization construction of artificial organs and tissues.

The invention provides a bone organ model as well as a construction method and application thereof, and the method comprises the following steps: arranging a biological material with a micropore array in a cell culture plate to obtain a bone organ chip; suspending the initial stem cells in a culture medium, and promoting the cells to form a spherical structure through cell aggregation or by using a non-adhesive culture surface, so as to obtain cell spheres; and culturing the cell spheres in the bone organ chip by adopting the culture medium for constructing the bone organ model to obtain the bone organ model. The skeletal organ is successfully constructed through in-vitro self-organized 3D co-culture initial stem cells including embryonic stem cells, induced pluripotent stem cells, bone marrow mesenchymal stem cells, osteoblasts, bone cells, all levels of osteogenic precursor cells, osteogenic-like cells and MC3T3-E1 cells, and the skeletal organ can become an important tool for researching and treating bone related diseases.

The invention belongs to the field of stem cells, and particularly relates to a method for inducing porcine embryonic stem cells to differentiate skeletal muscle cells by using a complete small molecule compound. The method comprises the following steps: S1, an induction stage: culturing the porcine embryonic stem cells in a culture medium for two days, and replacing with culture medium culture in the induction stage; s2, a differentiation stage: a differentiation stage culture medium is used for culture. The method is simple in operation process and high in efficiency, and large-scale production of the cell meat is facilitated while differentiation of the porcine embryonic stem cells into the skeletal muscle cells is achieved.

The invention relates to a method for induced differentiation of skeletal muscle cells by porcine embryonic stem cells. Comprising the following steps: (1) constructing a PAX7-overexpressed porcine embryonic stem cell stable cell line; (2) induced differentiation of skeletal muscle cells; (3) performing immunofluorescence identification; wherein the step (1) specifically comprises the following steps: 1.1, constructing a DOX (deoxyribonucleic acid) induced PAX7 expression plasmid PiggyBac-TRE3G-EF1a-PAX7; 1.2, performing electrical transformation on the porcine embryonic stem cells cultured for two days, and adding Buffer E into an electrical transformation cup; taking Buffer R, mixing plasmid and PBase, uniformly mixing, and re-suspending cell precipitate; 1.3, after electrotransformation is finished, the cells are planted on the feeding layer, Y-27632 is added into the culture medium, and the culture medium without Y-27632 is replaced with the culture medium without Y-27632 on the second day; and 1.4, after culturing for 3-4 days, selecting the porcine embryonic stem cells which are successfully subjected to electrotransfection for amplification culture, and naming PAX7-PESCs.

The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, hypo-immune pluripotent cells, cells that have been derived therefrom, and cells that have been biologically differentiated therefrom into particular tissue lineages that are ABO blood type O Rhesus Factor negative or otherwise evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

The invention provides a cognitive function in-vitro simulation method based on a microelectrode array (MEA) and brain organs and application of the cognitive function in-vitro simulation method, and belongs to the crossing field of brain organ in-vitro model construction, neural engineering, brain-like intelligence and the like. In an in-vitro environment, external signal (such as sound) information is converted into electrical stimulation input capable of being perceived by brain organs in an MEA electrical stimulation mode, so that the brain organs gradually learn and identify external signals in repeated electrical stimulation; after elution stimulation for a period of time, the reduction condition of recognition accuracy is observed, namely, the important memory and forgetting process in the cognitive function is simulated. According to the method, the electrophysiological response and the biological mechanism change of the brain organs under external electrical stimulation can be quantitatively evaluated, and a new possibility is provided for exploring the advanced cognitive function by utilizing the brain organs.

The invention discloses a micro-fluidic chip for vitrification cryopreservation of oocytes or embryos and a preparation method and application of the micro-fluidic chip. The micro-fluidic chip comprises a micro-fluid channel layer, and the micro-fluid channel layer is arranged in the micro-fluid flowing direction; the microfluid channel layer comprises one or more solution inflow channels, a snakelike mixing channel, one or more shunt channels, a snakelike channel, a cell storage chamber and a waste liquid discharge channel which are communicated in sequence; wherein a first micro-column array is arranged at an outlet of the cell storage chamber, and a second micro-column array is arranged in a channel outside an inlet of the cell storage chamber; and a cell channel is communicated between the cell storage chamber and the second micro-column array. The micro-fluidic chip can realize the integration of operations such as vitrification cryopreservation and rewarming, reduces the cell transfer frequency, avoids pollution, improves the treatment efficiency, can significantly improve the survival rate of oocytes or embryos after rewarming, and can further promote the development of an assisted reproduction technology.

The invention relates to the technical field of cell differentiation and the technical field of myocardial tissue regenerative medicine, in particular to a method for rapidly inducing directional differentiation of embryonic stem cells into myocardial cells in vitro. A matrix sandwich method is adopted, specific small molecule compounds are added in different time periods to induce the embryonic stem cells to differentiate towards the myocardial cells, and nearly 80% of myocardial cells can be obtained on the seventh day of induced differentiation. Compared with a traditional in-vitro myocardial differentiation induction scheme, the induced differentiation method provided by the invention has the advantages that the variety of related small molecules is few, the dosage is low, the induced differentiation time can be effectively shortened from 15 days to 7 days, the induced differentiation cost is saved, and the method is suitable for large-scale popularization and application. A novel way which is more economical, simpler, more convenient, more stable and more efficient is provided for the production of the stem cell-derived myocardial cells; the cardiac muscle cells obtained by induced differentiation are relatively high in purity and relatively wide in application prospect, and are of great significance to research on drug screening, myocardial regenerative medicine and cardiac developmental biology.

The present disclosure provides methods and systems directed to isolation of circulating fetal cells (CFCs) from maternal biological samples of pregnancy-related states. A method for identifying genetic disorders of the fetus (or fetuses) of a subject may involve assaying a biological sample derived from the subject to isolate CFCs, and characterizing the biomarkers, such as the sequence of genetic material or abundance of gene expression material, from the CFCs to determine the presence or absence of a pregnancy-related states, such as a genetic order or ongoing health risk to the mother or fetus.

The invention provides a decellularized amnion matrix hydrogel and a preparation method thereof. The preparation method comprises the following steps: amnion tissue pretreatment, cleaning, decellularization, grinding, freeze-drying, digestion and acid-base neutralization. According to the decellularized amnion matrix hydrogel, active cells are removed while collagen, fibronectin, glycoprotein and other components in an amnion cell matrix are reserved, and the immunogenicity of the decellularized amnion matrix hydrogel is reduced from the source. The decellularized amniotic membrane matrix hydrogel provided by the invention can simulate the microenvironment of in-vivo cells, provides support and signals required by cell adhesion and growth, can be used for constructing a tissue engineering scaffold, and provides support for directional growth and tissue regeneration of cells. Besides, the decellularized amniotic membrane matrix hydrogel can also be used as a drug carrier for in-vivo drug release and treatment, and has very high application potential in medical research and clinical application.

The invention discloses a culture solution for reducing lipid of animal embryos before freezing as well as a preparation method and application of the culture solution. The culture solution is prepared by adding bezafibrate and cholic acid into an NCSU23 culture solution. The invention also discloses a preparation method of the culture solution, which comprises the following steps: preparing an NCSU23 culture solution, and adding bezafibrate and cholic acid into the NCSU23 culture solution. Compared with a conventional NCSU23 culture solution, the culture solution provided by the invention has the advantages that the added bezafibrate and cholic acid have a synergistic lipid-lowering effect, so that the content of lipid in an embryo can be remarkably reduced, and the survival rate and the blastocyst hatching rate after the embryo is frozen and unfrozen are finally effectively improved. The culture solution provided by the invention has application prospects in the aspects of animal embryo lipid reduction, frozen embryo survival and development and the like.

The present invention relates to a method for culturing different types of cell in the same culture medium, to a method of culturing cells at high densities and to cell cultures comprising different types of cell.

A brain organoid containing optic vesicles generated based on H9 induction and an eye-brain fusion culture method thereof are provided. H9 embryonic stem cell induction is used to generate a brain organoid containing optic vesicles with primitive visual field. Based on an established optic vesicle brain organoid culture system, microscopic imaging is combined with specific marker antibodies related to early retinal development and photoreceptor cell maturation to structurally and functionally identify the brain organoid containing optic vesicles.

The invention belongs to the technical field of biomedicine, and particularly relates to a preparation method of human nourishing stem cells induced by human extended potential stem cells, which comprises the following specific steps: step 1, converting H9 human embryonic stem cells into adult extended potential stem cells on the basis of a feeder-layer-free system: (1) coating culture dishes with Matrigel, adding 1ml of Matrigel working solution into 35 dishes, and uniformly stirring; placing in an incubator at 37 DEG C overnight, and fully coating the dish bottom with the substrate for later use; according to the application, H9 human embryonic stem cells are converted into adult extended potential stem cells on the basis of a feeder-layer-free system; based on a human trophoblast stem cell culture system, feeder-layer-free human extended potential stem cells are differentiated into induced human trophoblast stem cells, and finally the induced human trophoblast stem cells are identified and induced to differentiate, so that interference of feeder-layer cells on the induced trophoblast stem cells is eliminated, and the induction efficiency of the induced trophoblast stem cells under the feeder-layer-free system is ensured.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and / or more “youthful” gene expression relative to cells obtained from donated tissue.

The invention discloses an artificial breeding method of epinephelus fuscoguttatus and pink pterus coerulescens hybrid species, which comprises the following steps: screening healthy epinephelus fuscoguttatus as a female parent, screening healthy pink pterus coerulescens as a male parent, and carrying out enhanced breeding on the male parent and the female parent, the gonad maturation of the parent is promoted; the method comprises the following steps: collecting egg liquid of a female parent and semen of a male parent, inseminating to obtain a fertilized egg, incubating the fertilized egg to obtain a hybrid spot, performing authenticity identification on the hybrid spot by using one or more of sequences SEQ ID NO.1-SEQ ID NO.8, and determining that the hybrid spot inherits genetic information of the female parent and the male parent. The technical blank of crossbreeding of the pink pink bass as the parent grouper is filled, so that the hybrid obtained by hybridizing the epinephelus fuscoguttatus and the pink pink bass is reliable in authenticity, and inherits genetic information of male and female parents on the molecular level.

The invention discloses hydrogel for 3D culture of stem cells / organoids and a preparation method of the hydrogel, and belongs to the technical field of biological materials. The hydrogel for 3D culture of stem cells / organoids is formed by a four-arm polyethylene glycol macromolecular polymer, the polyethylene glycol macromolecular polymer has a maleimide group (PEG-4MAL) at each terminal, is coupled with an adhesive peptide containing cysteine, and is obtained by cross-linking with mercapto polyethylene glycol (PEG-SH). The hydrogel is beneficial to organoids, the stem cells are high in growth rate and short in culture period, and the obtained organoids are high in maturity, uniform in size, high in bionic capacity and high in application value. Therefore, the prepared novel hydrogel material provides a more ideal microenvironment for culture of cells and organoids, and promotes application and development of regenerative medicine and tissue engineering.

The invention relates to the field of cell biology, and particularly discloses a method for preparing mesoderm progenitor cells from human pluripotent stem cells and an induced differentiation culture medium of the mesoderm progenitor cells. The method comprises the following steps: inoculating human pluripotent stem cells in a single cell state into a culture dish covered with matrigel; and inducing the human pluripotent stem cells to be differentiated into the mesoderm progenitor cells within 1-3 days by using the mesoderm progenitor cell induced differentiation culture medium. Wherein the mesoderm progenitor cell induced differentiation culture medium is composed of a basic culture medium and an additive, and the additive contains a B-27 additive, non-essential amino acid, glutamine, ascorbic acid, polyvinyl alcohol, a GSK-3 inhibitor and a CDK8 inhibitor. According to the method, the human pluripotent stem cells are subjected to induced differentiation by using the mesoderm progenitor cell induced differentiation culture medium with specific composition, the method does not depend on cloning of the pluripotent stem cells, a large number of high-uniformity mesoderm progenitor cells can be obtained through induced differentiation within 1-3 days, the induction efficiency is high, and the stability is high.

The present invention relates to pluripotent stem cell comprising an expression construct for expression of a CEBPα protein and an expression construct for expression of an ADIG protein. The invention further provides for methods of producing adipocytes comprising the pluripotent stem cells and for foodstuff comprising the adipocytes or pluripotent stem cells.

The present disclosure relates to a method for producing an inner ear organoid with improved differentiation efficiency of hair cells. The inventors of the present disclosure have confirmed that when retinoic acid is treated at the stage of formation of the lamina propria during the production of an inner ear organoid, the differentiation potential of hair cells is excellent. Therefore, it is expected that the inner ear organoid produced according to the production method of the present disclosure can be advantageously utilized in hearing loss disease modeling, drug screening and regenerative medicine.